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Abstract 
 
Intrinsic stress response pathways are frequently mobilized within tumor cells. The  mediators of these 
adaptive mechanisms and how they contribute to carcinogenesis remain poorly understood. A striking 
example is Heat Shock Factor 1 (HSF1), master transcriptional regulator of the heat-shock response. 
Surprisingly, we find that simple compromise of a tumor suppressor, Neurofibromatosis Type 1 (NF1), 
increases HSF1 levels and triggers its activation. As a consequence, Nf1-null cells acquire tolerance to 
proteotoxic stress. This activation of HSF1 depends on dysregulated MAPK signaling. HSF1 in turn 
supports MAPK signaling. In mice, Hsf1-deficiency impedes NF1-associated carcinogenesis by 
attenuating oncogenic RAS/MAPK signaling. In cell lines from human Malignant Peripheral Nerve 
Sheath Tumors (MPNSTs) driven by NF1 loss, HSF1 is over-expressed and activated. This activation is 
required for tumor cell viability. In surgical resections of human MPNSTs, HSF1 is over-expressed, 
translocated to the nucleus and phosphorylated. These findings reveal a surprising new biological 
consequence of NF1-deficiency: activation of HSF1 and an ensuing addiction to this master regulator of 
the heat-shock response. The loss of this tumor suppressor’s function engages an evolutionarily 
conserved cellular survival mechanism that, ironically, impairs survival of the whole organism by 
facilitating carcinogenesis. 
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Introduction 
Evolutionarily conserved from yeasts to humans, the heat-shock transcription factor, HSF1, is activated 
by a broad range of stressors that extend far beyond heat, including heavy metals, UV radiation, 
hypoxia, desiccation, and acidosis (1). During activation, HSF1 undergoes phosphorylation and other 
post-translational modifications, trimerization and nuclear translocation. This results in rapid, high 
affinity binding of HSF1 to consensus Heat Shock Elements (HSE) within the promoters of target genes 
(2). Such binding drives the induction or suppression of hundreds of genes in mammalian cells (3).  
 
The adaptive response that is unleashed by HSF1 activation is critical for maintaining 
homeostasis of the cell’s proteome, mediated in large part by increased expression of classical heat-
shock proteins such as HSP27, HSP70 and HSP90 (4). However, the impact of HSF1 activation goes 
far beyond these chaperones. It helps coordinate a range of fundamental cellular processes that are 
important to the fitness of malignant cells including cell cycle control, ribosome biogenesis, protein 
translation, and glucose metabolism (5). As a result, HSF1 both facilitates initial oncogenic 
transformation and also maintains the malignant phenotype of established cancer cell lines driven by a 
wide range of mutations. In mice and cell culture, genetic ablation of Hsf1 expression potently impairs 
tumorigenesis and cellular transformation driven by oncogene activation or tumor suppressor loss (5).  
The importance of HSF1 in enabling malignancy has been demonstrated by other recent work as well 
(6-8). Given the importance of HSF1 in diverse survival mechanisms and cancer, we sought here to 
investigate factors that might increase its transcriptional activity during tumorigenesis.   
 
Neurofibromatosis Type 1 (NF1) is a common hereditary cancer syndrome associated with 
dysregulation of RAS activity (9). Tumor predisposition results from loss-of-function mutations in the 
NF1 gene, which encodes neurofibromin, a 280 kD protein possessing a central domain with Ras 
GTPase Activating Protein (GAP) activity (10). Consistent with neurofibromin functioning as a negative 
regulator of RAS, NF1-deficient cells are hyper-responsive to several growth factors that signal via the 
Dai, Santagata et al. July 3rd, 2012 
 
4 
 
RAS/MAPK pathway (11). Indeed, when over-expressed, the GAP-related domain (NF1-GRD) can 
down-regulate RAS-mediated mitogenic signaling (12).  
 
Unexpectedly, we found that the tumor suppressor Nf1 is a strong regulator of HSF1 levels and 
activity. Indeed, genetic compromise of Nf1 is alone sufficient to cause an immediate activation of 
HSF1 in cell culture. HSF1 levels are also increased in tumor samples removed directly from NF1 
patients. Having found that Nf1 regulates HSF1 function, we investigated the underlying mechanism(s) 
of this control as well as its functional consequences. We demonstrate that HSF1 is embedded in the 
dysregulated MAPK/RAS signaling that is characteristic of NF1, and that HSF1 participates in a feed-
forward loop that facilitates tumorigenesis in mice and humans. Based on these findings, HSF1 now 
emerges as a previously unsuspected but clinically relevant modifier of NF1-associated tumorigenesis. 
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Results 
Nf1-deficiency up-regulates HSF1 and activates the heat-shock response 
Given the importance of HSF1 in supporting tumorigenesis we sought to identify genes that might 
modulate HSF1 function and the transcriptional response that it regulates. We screened a focused 
library of lentiviral inhibitory short hairpin RNAs (shRNAs) targeting 175 genes that were selected 
based on 1) Gene Ontology or Panther annotation under the categories of heat-shock, stress response, 
sensitivity to stress, protein folding or protein degradation and  2) iHOP interactome data indicating 
direct interaction with HSF1 (Supplemental Figure 1). NF1 was added to the list because a deletion 
mutation of its yeast homolog reduces thermotolerance in that organism (13).  
 
HSF1 activation was monitored using NIH3T3 cells stably engineered to express an eGFP-
firefly luciferase fusion controlled by a highly HSF1-dependent promoter (14). Luminescence per well 
was recorded five days post lentiviral transduction. As expected, shRNAs targeting Hsp27/Hspb2, 
Hsp47/Serpinh1, α(B)-crystallin/Cryab and several Hsp40 family members (Dnajb6 and Dnajc17) 
strongly activated the heat-shock reporter (Figure 1A). Hairpins targeting individual Hsp90 and Hsp70 
isoforms resulted in only weak reporter induction, most likely because shRNA targeting of individual 
isoforms may be insufficient to impair function of the many isoforms comprising the HSP70 and HSP90 
class of chaperones. Surprisingly, two independent Nf1-targeted shRNA hairpins were among the very 
strongest activators.   
 
Next, we examined the impact of stable Nf1 knockdown on the activation of HSF1 in a mouse 
embryonic fibroblast (MEF) cell line immortalized with the HPV16 E6/E7 oncoproteins (6). Compared to 
a scrambled (Scram) control shRNA, two independent shRNAs (#39 and #42) efficiently suppressed 
the neurofibromin protein levels and induced an increase in the level of the heat-shock protein HSP72, 
a classic HSF1 target (Figure 1B). The hairpin that suppressed neurofibromin expression most 
efficiently (#42) also induced the strongest expresson of HSP72. We further examined transcript levels 
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of HSF1 target genes by real-time quantitative RT-PCR analysis in these Nf1-knockdown cells. 
Compared to the control, knockdown of Nf1 by both #39 and #42 shRNAs increased transcript levels of 
a collection of Hsp genes including Hsp70s (Hsp72/Hspa1a and Hspa4l), Hsp40s (Dnajb1 and Dnajb2), 
Hsp90 (Hsp90aa1) and a small Hsp family member (Hspb8) (Figure 1C). Hairpin #42 induced the 
strongest expression of these Hsp genes. These results demonstrate that reducing Nf1 expression can 
activate the heat-shock response in pre-malignant cells.  
 
To measure the effect of Nf1-targeted hairpins on HSF1 protein levels, we immunoblotted 
lysates (Figure 2, A and B) from the same stably transduced Nf1-knockdown cells. HSF1 normally 
shuttles between the nucleus and cytoplasm, but differential residence time in these compartments 
results in predominantly cytoplasmic localization under basal conditions. Upon activation, however, 
HSF1 accumulates in the nucleus where a portion becomes tightly bound to DNA (Supplemental Figure 
2A). Both #39 and #42 shRNAs increased HSF1 levels and translocation of HSF1 to the nucleus 
compared to the control shRNA (Figure 2, A and B). They also induced  phosphorylation of HSF1 at 
serine residue 326 (p-S326) (Figure 2, A and B), a modification that is strongly associated with HSF1 
activation in vivo by thermal and chemical stressors (15). The kinases or signaling pathways 
responsible for this key modification has yet to be defined, but consistent with activation of HSF1 by 
stable Nf1 knockdown, HSP72 protein levels were elevated (Figure 2B). The transcript level for Hsf1 
was not altered by Nf1-knockdown (Supplemental Figure 2B), suggesting post-transcriptional regulation 
of HSF1 levels.  
 
To confirm the effects demonstrated by shRNA knockdown experiments, we further tested the 
effect of Nf1-deficiency using primary MEFs in which the Nf1 locus was disrupted by gene-targeting.  
Primary cultures derived from both Nf1 heterozygous (+/-) and null (-/-) embryos had increased HSF1 
protein levels compared to their wild-type (+/+) counterparts (Figure 2, C and D). Null cells displayed 
even higher levels of HSF1 protein and greater induction of HSP72 than heterozygous cells (Figure 2, 
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C and D). Nf1-null cells also had an increase in both nuclear HSF1 and the activating p-S326 
modification than wild-type cells (Figure 2D).  
 
Dysregulated MAPK signaling mediates HSF1 activation 
How might Nf1 loss increase p-S326, nuclear accumulation of HSF1 and total HSF1 levels? A hallmark 
of the NF1 phenotype is dysregulation of RAS activation with downstream effects on the MAP 
kinase/ERK (MAPK/ERK) signaling cascade. Hence, Nf1 loss could activate HSF1 through the MAPK 
pathway. We tested this possibility using U0126, a potent and selective inhibitor of MAP Kinase Kinase 
(MEK1 and 2), the immediate upstream activators of ERK 1 and 2. U0126 reduced activation-
associated phosphorylation of HSF1 as well as its nuclear accumulation, leading to a decline in HSP72 
levels in both control and Nf1-knockdown cells (Figure 2B). Interestingly, U0126 had a greater effect on 
Nf1-knockdown cells than on control cells (Supplemental Figure 2C). U0126 exhibited similar effects on 
primary Nf1-/- MEFs to those seen in knockdown cells (Figure 2D and Supplemental Figure 2D). The 
compound also caused an increase in HSF1 phosphorylation and HSP72 level in primary Nf1+/+ MEFs 
(Figure 2D). This likely reflects a biological difference between immortalized and primary cells. Either 
blocking this trophic signaling pathway is stressful to primary, Nf1-wild type cells or basal MAPK 
activities actually repress HSF1 activation in these cells. In any case, the data in Nf1-deficient cells 
indicate that hyperactivated MAPK signaling contributes to HSF1 Ser326 phosphorylation, nuclear 
translocation and activation.  
 
      Next we used a heat-shock reporter assay to examine the effect of dysregulated MAPK signaling on 
HSF1 transcriptional activity in HEK293T cells. In the absence of environmental insults, the transfected 
reporter demonstrated a modest level of activation that was further enhanced by overexpression of 
HSF1 (Figure 2E). Inhibition of endogenous MEK activity by U0126 significantly suppressed both basal 
and HSF1-driven reporter activity (Figure 2E). To further validate the role of hyperactive MAPK 
signaling in HSF1 phosphorylation and activation, we transiently transfected HEK293T cells with a 
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dominant negative MEK1 mutant (MEK1AA), in which two key serine residues at 218 and 222 are 
substituted with alanine (16). In agreement with our U0126 data, expression of MEK1AA impaired HSF1 
Ser326 phosphorylation as well as HSF1-mediated reporter activation (Figure 2, F and G). Although 
significant, mutant MEK1 reduced reporter activity less than U0126. This is likely due to both the limited 
efficiency of HSF1 and MEK1AA co-transfection and the potential for MEK2 compensatory effects. 
Together these data indicate that MEK hyperactivation is important for HSF1 S326 phosphorylation and 
activation.  
 
 Does MAPK signaling also underlie the increase in total HSF1 protein? Because HSF1 mRNA is 
not increased in NF1-deficient cells, we investigated post-transcriptional mechanisms that might 
contribute to increasing HSF1 protein after NF1 loss. Interestingly, HSF1 levels in control cells (Scr) 
increased by more than two-fold following proteasome inhibition with MG132 but there was only subtle 
change in HSF1 levels in Nf1-knockdown cells (#42) (Figure 2H and Supplemental Figure 2E). This 
finding suggested that HSF1 is a substrate for the proteasome but that its degradation is impaired in 
Nf1-deficient cells.  
 
 To further explore the impaired degradation of HSF1 in Nf1-deficient cells and to establish a link 
to MAPK signaling, we immunoprecipitated polyubiquitinated HSF1 from control and Nf1-knockdown 
cells (17). While polyubiquitinated HSF1 was readily detected in control cells (Scr), HSF1 
polyubiquitination was markedly diminished in Nf1-knockdown cells (#42) (Figure 2I). Strikingly, 
inhibiting MEK with U0126 re-established polyubiquitination of HSF1 (Figure 2I). Thus, MEK 
hyperactivation also regulates HSF1 polyubiquitination and proteasomal degradation. 
 
HSF1 activation by Nf1 loss induces stress tolerance 
Next we asked if loss of Nf1 alone, and subsequent activation of HSF1, might be sufficient to provide 
cells with a survival advantage in the face of increased levels of proteotoxic stress. To test this, we 
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generated primary MEFs from mice carrying targeted Hsf1 or Nf1 knockouts. Because the Nf1-/- 
genotype is embryonic lethal (18) and Hsf1-/- mice have reproductive defects (19),  it was necessary to 
screen over 120 embryos in order to isolate MEFs with four distinct genotypes: Hsf1+/+ cells that were 
either Nf1+/+ or Nf1-/- and Hsf1-/- cells that were Nf1+/+ or Nf1-/-. We then measured the changes in 
cell number in the presence of three chemically and mechanistically distinct cellular stressors: the 
proteasome inhibitor MG132 (Figure 3A), the HSP90 inhibitor radicicol (Figure 3B) and the thiol-
reactive compound Withaferin A (WA) (Figure 3C) (20, 21). Unlike the situation in yeast where deletion 
of the Nf1 homolog IRA2 reduces thermotolerance, MEFs lacking Nf1 (Hsf1+/+,Nf1-/- MEF) were 
significantly more resistant to all three proteotoxic stressors than wild-type MEFs (Figure 3, A-C). In 
fact, Hsf1+/+,Nf1-/- MEFs showed an increase in cell number at low concentrations of MG132 and WA.  
In contrast, disrupting Nf1 in Hsf1-/- cells did not confer resistance to the stressors (Figure 3, A-C).  
Thus, the tolerance of Nf1-deficient cells to proteotoxic stress is mediated by Hsf1. 
 
Hsf1 compromise suppresses tumorigenesis in mice 
Because tumorigenesis imposes diverse stresses on the physiology of cells, we wondered whether 
HSF1 activation and the ensuing acquisition of tolerance to proteotoxic stress could facilitate NF1-
associated tumorigenesis in vivo. To investigate, we turned to NPcis mice. The tumor predisposition 
syndrome caused by NF1 loss in humans has proven difficult to faithfully model in mice. Homozygous 
germline disruption of the Nf1 gene is embryonic lethal predominantly due to defects in cardiovascular 
system development (22). Heterozygous mice display modest tumor predisposition, but they do not 
develop the classic spectrum of lesions characteristic of the human disease, especially neurofibroma 
and MPNST (23). The observation that the tumor suppressor TP53 is frequently lost in human MPNSTs 
prompted development of mouse models in which alleles of the closely linked Trp53 and Nf1 genes are 
disrupted on the same chromosome (24, 25). The chromosome bearing deletion of both Nf1 and Trp53 
in cis is designated NPcis. Heterozygotes (NPcis+/-) develop soft tissue sarcomas resembling human 
MPNSTs with high frequency. Due to the close proximity of the Trp53 and Nf1 genes (in humans as 
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well as mice), such tumors often demonstrate loss of heterozygosity (LOH) for the remaining wild-type 
alleles of both genes.   
 
To examine the effect of HSF1 in this model, we crossed NPcis+/- mice with Hsf1+/- mice.   
NPcis+/-, Hsf1+/- offsprings were intercrossed to produce the following genotypes: 1) NPcis+/+, 
Hsf1+/+; 2) NPcis+/+, Hsf1-/-; 3) NPcis+/-, Hsf1+/-; 4) NPcis+/-, Hsf1-/-; and 5) NPcis+/-, Hsf1+/+.   
Genotypes 1 and 2 served as controls for the effect of Hsf1 knockout on otherwise wild-type mice.  As 
expected these control mice had long-term tumor-free survival (Figure 4A). Genotypes 3, 4 and 5 
tested for the effect of Hsf1 dosage on tumorigenesis in the NPcis background. All NPcis mice with 
wild-type Hsf1 developed tumors by about 250 days, with a median tumor-free survival of only 154 days 
(Figure 4A). In contrast, NPcis mice with hemizygous or homozygous Hsf1 knockout both enjoyed 
significantly prolonged tumor-free survival, with median survivals of 235 and 206 days respectively.  
 
The difference in tumor-free survival between homozygous and heterozygous Hsf1 knockouts, 
however, was not statistically significant. This contrasts with our previous results in mice carrying a 
hotspot mutation in Trp53. In that case Hsf1-heterozygous mice also had improved outcome compared 
to Hsf1-wild type mice, but Hsf1-null mice survived even longer. While being a prominent longevity 
factor in nematodes (26, 27), the influence of HSF1 on mammalian lifespan has been little explored. In 
some strains, Hsf1 compromise has no effect on lifespan (5, 28). However, we find that in the mixed 
background used for our NPcis experiments, Hsf1 knockouts had a shorter lifespan than wild type 
controls. This effect is evident in the depiction of overall survival provided in supplemental Figure 3A 
which includes deaths from all causes, not solely tumor-related deaths as used for analysis of tumor-
free survival (Figure 4A). Thus, the additional survival advantage that might have been conferred on 
tumor-associated mortality by loss of the second Hsf1 allele was likely masked by general effects of 
Hsf1 on lifespan in the NPcis strain. 
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           To characterize the tumors arising in NPcis mice we first examined their HSF1 status. In the 
same sections, MPNST tumor cells had much stronger HSF1 immunoreactivity than adjacent normal 
tissues such as nerve (NV; Figure 4B). The absence of reactivity in tumors arising in Hsf1-null mice 
confirmed the specificity of the HSF1 staining.   
 
 NF1 patients can develop a broad range of tumor types, most of which also occur in NPcis mice 
(Supplemental Figure 4). To capture all tumor types arising in this model a full necropsy was performed 
on each euthanized animal and all major tissues were harvested for histological examination. In 
addition to prolonging tumor-free survival, Hsf1-deficiency altered the distribution of tumor types arising 
in this model. Compared to Hsf1 wild-type mice, the incidence of lymphoma, neuroblastoma, 
angiosarcoma, osteosarcoma, pheochromocytoma, and histocytic sarcoma were all reduced in Hsf1 
null mice (Supplemental Figure 3B). Surprisingly, the overall incidence of MPNSTs and gliomas was 
not significantly different. Excluding gliomas and MPNSTs, however, tumor incidence was significantly 
lower in Hsf1 null mice (5.9%) and Hsf1 hemizygous mice (26.9%) mice compared to Hsf1 wild-type 
mice (60.9%). The MPNST arising in Hsf1 +/+, +/- and -/- tumors appeared histologically similar. 
 
Although MPNST incidence did not differ, Hsf1-deficiency did prolong survival time in mice that 
only developed MPNSTs (Figure 4C). This effect was statistically significant in Hsf1 hemizygous mice 
(p=0.0152), and there was a trend toward significance in Hsf1-null mice (p=0.0869). Given the late-
occurring, slowly progressing behavior of glioma in this NPcis model, the apparent increase in glioma 
incidence in Hsf1-deficient mice is likely due simply to their prolonged survival. Indeed, there was a 
strong positive correlation between glioma incidence and median survival across Hsf1 genotypes 
(Supplemental Figure 3C).   
 
To circumvent placental defects associated with the Hsf1 null state in highly inbred genetic 
backgrounds (19), Hsf1 mice were maintained on a mixed genetic background (129/SvJ and Balb/cJ). 
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Previously two genetic loci, mapping to chromosome 15 and 19 respectively, as well as sex-specific 
effects have been reported to modify tumorigenesis in the NPcis model (29,30). To address potential 
confounding effects of these modifiers in our study, we examined the correlation of mapped genetic loci 
or sex with animal survival (Supplemental Table, 1 and 2). Neither the states of these loci nor sex 
demonstrated a significant effect on survival (Supplemental Figure 5). Taken together, our data 
establish Hsf1 as a previously unreported modifier of NF1-associated tumorigenesis in this mouse 
model. 
 
HSF1 supports MAPK/ERK signaling in Nf1-deficient cells 
In light of the importance of dysregulated MAPK signaling we had seen in cell culture, we next 
investigated the effect of Hsf1 loss on the MAPK/ERK pathway in tumors arising spontaneously in 
NPcis mice. All MPNSTs demonstrated comparable levels of total ERK protein but those arising in 
Hsf1-null mice had significantly lower levels of phospho-ERK compared to MPNSTs from Hsf1-wild type 
mice (Figure 5A). This finding is consistent with our previous observations, in other contexts, that HSF1 
supports transformation and tumorigenesis by oncogenic RAS (6).   
 
Strikingly, HSF1 supported MAPK signaling not only in Nf1-deficient tumors but even in primary 
MEFs. In the homozygous NPcis mutant background, primary MEFs that were Hsf1 heterozygous or 
null displayed much reduced ERK phosphorylation compared to their Hsf1 wild-type counterparts 
(Figure 5B). Reduced MAPK signaling in both tumors and primary cells that are Hsf1-deficient 
demonstrates a critical role for HSF1 in supporting activity of the RAS/MAPK pathway. Taken together 
with data from Figure 2, we propose that loss of Nf1 activates HSF1 at least in part via activation of the 
MAPK/ERK pathway and that HSF1, in turn, is necessary to support MAPK signaling.  
 
HSF1 is activated in NF1-deficient human tumors 
Results in mouse models do not always reflect the pathophysiology of human disease. Does a 
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pathobiology comparable to that seen in NPcis mouse model operate in humans? To address this 
question, we first examined HSF1 activation status in a panel of five human cell lines derived from 
patients clinically diagnosed with Neurofibromatosis Type I. These lines express Schwann cell markers 
such as S100β and p75 neurotrophin receptor, consistent with Schwann cell origin (31). Three cell lines 
(sNF96.2, 90-8TL and S462) were devoid of neurofibromin, consistent with their reported NF1 mutation 
status (32-34). Despite their clinical derivation, however, two of the lines, sNF02.2 and sNF94.3, 
express full-length neurofibromin protein (32, 35, 36 and Figure 6A). While the specific NF1 mutation(s) 
in these two cell lines remain unknown despite sequencing of multiple exons, their elevated RAS-GTP 
levels suggest some impairment of neurofibromin function (37). However, these two lines exhibited 
significantly lower levels of activating phosphorylation of key RAS downstream effectors, C-RAF and 
MEK1/2 (16, 38, 39), compared to the three cell lines devoid of neurofibromin (Figure 6A). This result 
supports only partial loss of neurofibromin function in these two lines. 
 
In analyzing our panel of human MPNST cells, our distinct findings clearly demonstrate that 
HSF1 is activated to a greater degree in those cell lines lacking neurofibromin than in those expressing 
neurofibromin. First, levels of HSF1 and the highly HSF1-regulated heat-shock protein HSP72 were 
increased (Figure 6A). Second, by immunofluorescent staining, HSF1 was increased and localized to 
the nucleus (Figure 6B). Third, HSF1 was robustly phosphorylated at serine residue 326 (p-S326, 
Figure 6A). Fourth, HSF1 was trimerized, the characteristic state of the activated protein (Figure 6C).  
This activation was constitutive, occurring in the absence of environmental stressors.  
 
   Furthermore, consistent with the results in Nf1-deficient MEFs (Figure 2, B and D), U0126 
reduced Ser326 phosphorylation and nuclear translocation of HSF1 in MPNST cells (Figure 6, D and 
E). Thus, in human NF1 tumor cells aberrant MAPK signaling also critically regulates HSF1 activity. 
 
Human MPNST cells are addicted to HSF1 and to MEK signaling 
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Do these cell lines require HSF1 to maintain their malignant phenotype? To test this, we knocked down 
HSF1 expression with lentiviral shRNAs. First, we tested the efficacy of different hairpins on HSF1 
knockdown. As previously reported in other cell types (5), the hA6 hairpin was more effective than the 
hA9 hairpin in MPNST cells (Figure 7A). Suppression of HSF1 by both the hA6 and hA9 shRNAs 
markedly decreased cell number in lines lacking neurofibromin (Figure 7B). Moreover, transduction with 
hA6 caused a greater reduction than hA9, consistent with a dose-dependent effect of HSF1 on viability.  
As an additional control, we transduced one of the lines with low HSF1 levels that maintained 
neurofibromin expression with the same panel of lentiviral supernatants. Cell number was much less 
reduced, not only ruling out non-specific cytotoxicity as the basis for the activity of HSF1-targeted 
lentiviral preparations but also supporting the idea that NF1 function is only partially compromised in 
sNF02.2 cells.  
 
To provide mechanistic insight into the interplay of HSF1 and MAPK signaling in human MPNST 
cells, we examined the effect of HSF1 knockdown on phosphorylation of ERK, the downstream target 
of RAS/MAPK signaling. This endpoint had been strongly HSF1-dependent in both mouse tumors and 
NPcis MEFs (Figure 5). Compared to cells transduced with scrambled control hairpins, transduction 
with either hA6 or hA9 virus caused a marked decline in ERK phosphorylation, with hA6 again having 
the greatest effect (Figure 7C). RAS requires the scaffold protein KSR1 for efficient signaling of the 
MAPK/ERK pathway and KSR1 deletion inhibits RAS-driven oncogenesis (40, 41). HSF1 knockdown 
sharply reduced KSR1 levels in a dose-dependent manner. Because KSR1 function depends on 
molecular chaperones (42), the decrease in HSP72 and HSP90 levels following HSF1 knockdown 
(Figure 7C) could contribute to KSR1 loss. Consistent with this hypothesis, inhibition of HSP90 by 
geldanamycin reduced KSR1 protein levels and ERK phosphorylation in both S462 and 90-8TL cells 
(Figure 7D and Supplemental Figure 6A). As expected, levels of AKT, a known HSP90 client protein, 
were also reduced by geldanamycin.   
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To examine the role of KSR1 in maintaining the malignant phenotype of human MPNST cells, 
we transiently transfected a non-targeting and three independent KSR1-targeting siRNAs into S462 
cells. In these cells, knock down of KSR1 induced apoptosis, indicated by elevated levels of cleaved 
PARP and Caspase 7 (Figure 7E), and reduced cell number (Figure 7F). Overall, the data support a 
model in which, HSF1 enables the malignant phenotype of neurofibromin-deficient cells at least in part 
by stabilizing KSR1 and supporting dysregulated MAPK signaling. 
 
MEK kinase provides an attractive therapeutic target for human cancers. To examine the effects 
of MEK inhibition on human MPNST cells, S462 cells were treated with either U0126 or CI-1040, the 
first MEK inhibitor to enter clinical trials (43). Prolonged MEK inhibition over the course of several days 
markedly reduced the protein levels of HSF1, HSP90α, and KSR1 (Figure 8, A and B). Consistent with 
our observation that inhibiting MEK reconstitutes polyubiquitination of HSF1 (Figure 2I), enhanced 
HSF1 polyubiquitination was seen in S462 cells following overnight exposure to U0126 or CI-1040 
(Figure 8C).  
 
We also examined whether MEK inhibition reduced the cell number of human MPNST cells. 
Two neurofibromin-expressing MPNST cell lines and a normal diploid fibroblast control cell line were 
relatively resistant to MEK inhibition with CI-1040.  However, two of the three neurofibromin-deficient 
cell lines displayed enhanced sensitivity to CI-1040 treatment (Figure 8D). Why the third line, 90-8TL 
was relatively insensitive is unknown, but warrants further investigation. Previous reports suggest a 
number of factors could be involved including mutations in BRAF and PI3KCA (44, 45).  
 
Next we asked whether enhanced HSF1 function is sufficient to augment MAPK signaling. We 
generated isogenic S462 cells stably overexpressing HSF1 by viral transduction. Compared to cells 
stably transduced with LacZ gene, cells with HSF1 overexpression showed higher levels of KSR1 and 
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phospho-ERK (Figure 8E). This result was also reproduced in HEK293 cells and immortalized MEFs 
(Supplemental Figure 6, B and C). As expected, the levels of HSP90α and HSP72 were increased in 
these HSF1-overexpressing cells. These data, together with the role we have demonstrated for HSF1 
in supporting MAPK signaling, establish HSF1 as an important modulator of the RAS/MAPK signaling 
axis. Such a feed-forward loop could enable a powerful shift in the survival landscape that facilitates 
tumorigenesis (Figure 8F). 
 
HSF1 is over-expressed and activated in MPNSTs resected from patients  
To move from laboratory models to clinical material, we used both immunofluorescence (IF) and 
immunohistochemistry (IHC) to examine HSF1 levels and localization in a panel of ten human MPNST 
surgical resections. High levels of HSF1 were found in the nuclei of tumor cells in all of the specimens 
examined. HSF1 levels were markedly higher in MPNST cells than in surrounding normal tissues, 
including nerve and perineurium (Supplemental Figure 7A). Benign neurofibroma demonstrated an 
intermediate level (Supplemental Figure 7B). Co-IF also clearly demonstrated high HSF1 levels in 
MPNST cells but very low levels in the infiltrated nerve (Figure 9A). Consistent with our findings in mice 
(Figure 5) and cultured human tumor cells (Figure 6), we detected activation-associated 
phosphorylation of ERK at much higher levels in HSF1-overexpressing MPNST cells than nerve 
(Supplemental Figure 8). Intermediate levels of phospho-ERK were observed in benign neurofibroma 
(Supplemental Figure 8).    
 
In one specimen, we captured an MPNST developing from a neurofibroma; it is uncommon to 
observe a truly high-grade MPNST adjacent to its low-grade counterpart in an individual microscopic 
specimen. This opportune sample allowed us to visualize levels of HSF1 and assess its 
phosphorylation status during tumor progression. Captured side by side, HSF1 staining was indeed 
present in the nuclei of many cells in the neurofibroma but there was more intense staining for HSF1 
protein in the nuclei of MPNST cells (Figure 9B and Supplemental Figure 7A and B). While p-S326 
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HSF1 (p-HSF1) levels were heterogeneous in benign neurofibroma cells, levels were markedly higher 
and uniformly expressed in the MPNST cells consistent with increasing activation of HSF1 during tumor 
progression (Figure 9B). 
Dai, Santagata et al. July 3rd, 2012 
 
18 
 
Discussion 
HSF1, the master regulator of the heat-shock response in eukaryotes, is a powerful modifier of 
carcinogenesis (5-8). How HSF1 is activated in tumors, however, has been largely unknown. Though 
heat-shock proteins were known to be elevated in cancer, this was commonly ascribed to a classic 
“heat-shock response” in reaction to the environmental and proteomic stresses that are inherent to the 
malignant state. Here we report the surprising finding that HSF1 is activated by a simple genetic 
alteration that underlies, but precedes malignancy, loss of the Nf1 tumor suppressor. Upon loss of Nf1 
function, dysregulated MAPK signaling engages HSF1. In turn, HSF1 supports and further augments 
activation of the MAPK pathway to drive tumorigenesis. This feed-forward loop arises from intrinsic 
genetic alteration, not from environmental stress. Activation of HSF1 in this fashion allows cells to 
withstand a range of proteotoxic insults even during very early stages of tumorigenesis, thereby 
enabling the process. The same pathobiology is at work in NF1-associated malignancies in human 
patients where activation of HSF1 arises in neurofibroma and more robust and uniform activation of 
HSF1 then occurs during progression to MPNST. 
 
A new mode of HSF1 activation: Tumor suppressor loss 
During tumorigenesis, micro-environmental challenges such as nutrient deprivation and hypoxia (46) 
and cell-autonomous challenges such as genomic instability, altered metabolism, reactive oxygen 
species and the burden of mutated and misfolded oncoproteins must all be successfully managed by 
malignant cells to permit their survival (47, 48). These stresses, inherent to malignant transformation, 
progression, and metastasis are made tolerable by a range of innate adaptive responses. The HSF1-
mediated response is one of several critical systems that make adaptation not only possible but 
efficient. Other responses mediated by regulators such as Hypoxia-Inducible Factor 1 (HIF1), Nuclear 
factor kappa B (NFκB) and Stress-activated Protein Kinases, (p38 MAPK and JNK) participate as well 
to enable cancer cells to adapt and prosper (49-51). 
 
Dai, Santagata et al. July 3rd, 2012 
 
19 
 
Understanding how stress response regulators are engaged during malignant transformation is 
of both basic interest and potential therapeutic value. In the case of HSF1, the drivers of activation, the 
point in tumorigenesis when this occurs, and the functional consequences have remained poorly 
defined. The stimulus most widely assigned to drive HSF1 activation in cancer is increased substrate 
burden on the heat-shock protein/chaperone machinery. Dysregulation of the protein translation 
machinery (52), imbalanced protein production due to aneuploidy (53,54) and accumulation of mutated, 
highly chaperone-dependent oncoproteins all strain the chaperone machinery (55-57). Support for this 
model of HSF1 activation comes from observations that the HSP90-based chaperone machinery may 
be pressed to operate at its maximal capacity in cancer cells (58), thereby releasing HSF1 from a 
repressive complex with HSP90 (59).   
 
Alongside this model of HSF1 activation, we now describe another driver for HSF1 activation, 
loss of the tumor suppressor Nf1. Not only does HSF1 accumulate in the nucleus of neurofibromin 
deficient cells but total levels of HSF1 protein and activating phosphorylation of HSF1 all increase. This 
indicates a role for the HSF1-adaptive response even in the earliest phases of tumorigenesis, when 
dysplasia and pre-malignant alterations begin to arise. By coordinating the diverse biological processes 
required for tumorigenesis, HSF1 can play a critical role in providing a permissive cellular environment 
that cultivates the very inception of a neoplasm. Interestingly, in a recent study in breast cancer we 
observed that HSF1 is frequently activated in developing neoplasms prior to invasion while the tumor 
cells still remain in situ (60). Our findings in Nf1 null cells now suggest that HSF1 can be at work even 
earlier in tumorigenesis, before atypical changes in cell morphology become visually evident. 
Although NF1 was cloned almost 2 decades ago (61), our understanding of exactly how 
neurofibromin impacts growth, metabolism and survival to act as a key tumor suppressor remains 
incomplete. The findings reported here further expand our understanding of this tumor suppressor, 
revealing a previously unrecognized function for NF1 in modulating the  cellular response to proteotoxic 
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stress. The tumor suppressor NF1 prevents activation of the heat-shock response under basal 
conditions by restraining improper activation of the MAPK signaling. Upon NF1 loss, however, 
dysregulated MAPK signaling induces HSF1 phosphorylation, nuclear translocation and an increase in 
the level of HSF1 protein through impaired proteasomal degradation.  
 
Dysregulated MAPK signaling is important for HSF1 activation during tumor development, 
supporting a relationship between tumorigenesis and HSF1 activation that is deeply rooted in the 
molecular biology and signaling aberrations of NF1-associated tumorigenesis, not solely in 
environmental and proteotoxic triggers. The importance of MAPK signaling in HSF1 recruitment 
suggests that other mitogenic pathways dysregulated by dominantly acting oncogenes may also impact 
HSF1 activity (55). The question now arises: Is loss of other classical tumor suppressors such as p53, 
RB or PTEN alone sufficient to activate HSF1? It seems likely that it is a combination of many factors 
that evoke the robust activation of HSF1 observed in very high-grade tumors, compared to the more 
modest activation seen in their lower-grade counterparts from which they often develop. 
HSF1 shapes the tumor landscape 
What are the functional consequences of HSF1 activation? These are only beginning to 
emerge. Here, we found that Nf1 loss leads to an HSF1-dependent capacity to tolerate a broad range 
of proteotoxic perturbations. The chemical stressors we employed likely phenocopy some of the 
internal proteomic imbalances as well as the environmental pressures that tumors must accommodate 
during their initiation and progression. By fostering an ability to thrive in unfavorable conditions, HSF1 
ultimately can promote enhanced malignant behavior. Indeed, in a separate study of over 1,800 women 
with invasive breast cancer from the Nurses’ Health Study we recently found that HSF1 activation is 
associated with tumor size, histologic grade and likelihood of metastasis (60). This work demonstrates 
that HSF1 is an independent predictor of poor outcome in breast cancer (60). These strong 
epidemiological associations implicating HSF1 in malignancy are supported here by knockdown 
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experiments demonstrating a direct and critical role for HSF1 in promoting the viability of MPNST cells 
lines derived from advanced cancers.  
In addition to facilitating survival under stress, HSF1 also supports tumor growth through its 
integral role in a feed-forward loop supporting the pro-proliferative MAPK pathway. Not only is HSF1 
activated by MAPK signaling but its activation, in turn, robustly supports increased flux through this 
signaling axis both in MEF and in MPNST cells. By supporting this particular signaling pathway, which 
is central to the pathophysiology of NF1, HSF1 alters the NF1 phenotype, as suggested by our 
observation of  a shift in tumor spectrum and latency. How it might impact other features of clinical NF1 
such as neurodevelopmental abnormalities would be fascinating to investigate. Lastly, important as 
MAPK signaling may be, the impact of HSF1 on NF1-associated malignancies undoubtedly extends 
beyond effects on this one signaling pathway and is likely rooted in the compendium of diverse cellular 
processes that HSF1 uniquely regulates in tumors. 
HSF1 as a therapeutic target in NF1? 
The critical dependence of established MPNST cell lines on HSF1, the expression of HSF1 at high 
levels in surgical resection specimens and its activation-associated phosphorylation firmly establish the 
importance of HSF1 in enabling NF1-associated tumorigenesis in humans. Targeting HSF1 could 
represent a new way of approaching anti-cancer therapy. Non-genotoxic strategies would be 
particularly important in NF1 because patients are at markedly increased risk of developing treatment-
related myeloid leukemias after exposure to conventional alkylating agents (62). Moreover, our finding 
that HSF1 expression and activation are associated with malignant potential and outcome in breast 
cancer (60) suggests that HSF1 status should be evaluated as a potential novel prognostic marker for 
human NF1 malignancies, particularly MPNSTs. 
 
Is HSF1 a plausible therapeutic target? Genetic knockout of Hsf1 is sufficient to completely 
abrogate induction of the heat-shock response following temperature shift. Normal basal expression of 
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the major heat-shock protein classes is preserved, however, which makes HSF1 dispensable for 
growth and survival of mammalian cells under physiological conditions. Indeed knockout mice deficient 
for Hsf1 develop essentially normally and prosper under non-stress conditions (19, 63). This feature 
and our finding that even haploinsufficiency of Hsf1 impairs tumorigenesis suggest that a useful 
therapeutic index for selective inhibitors of HSF1 is likely to exist.   
 
Unfortunately, no small, drug-like inhibitors of the heat-shock response have yet been identified 
that target HSF1 in a convincingly specific manner. Most, if not all appear to act on the cascade of post-
translational modifications mediated by kinases, phosphatases, acetylases and conjugating enzymes 
involved in regulating HSF1 activation (64, 65). Discovery efforts are in their infancy, however, with 
great potential for further progress (64-67).   
 
Many important questions remain, but the findings reported here provide a deeper basic 
understanding of how cellular physiology accommodates constitutive loss of NF1 function. The adaptive 
HSF1 program set in motion enhances cell survival but comes at the cost of enabling tumor formation 
in this common cancer predisposition syndrome. Likely a similar phenomenon occurs in sporadic 
human cancers driven by other tumor suppressor abnormalities or even mutant oncogenes. 
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Methods 
Cells, tissues and reagents 
See Supplemental Experimental Methods for details.  
 
Real time quantitative RT-PCR: 
Total RNAs were extracted using a USB PrepEase RNA Spin Kit (Affymetrix). 100ng RNAs were used 
for reverse transcription using a Maxima First Strand cDNA Synthesis kit (Fermentas). Equal amounts 
of cDNA were used for quantitative RCR reaction using Maxima SYBR Green/ROX qPCR Master Mix 
(Fermentas). Signals were detected by an ABI 7500 Real-Time PCR System (Applied Biosystems). The 
sequences of individual primers for each gene are listed in the Supplemental Materials. 
 
Transfection and luciferase reporter assay: 
Plasmids were transfected into HEK293T cells with Arrest-In™ transfection reagent (Open 
Biosystems). The following plasmids were used in transfection experiments: pBabe-EGFP (generated 
from pEGFP-N3 plasmid), pBabe–MEK1AA (generated by site-directed mutagenesis), pHSE-firefly 
luciferase (Clontech), pCMV-renilla luciferase (Promega), and pBabe-HSF1 (Addgene#1948). 
Luciferase activities were quantitated using a Promega Dual-Glo® Luciferase Assay System using a 
VICTOR3 Multilabel plate reader (PerkinElmer). 
 
Tumorigenesis studies in NPcis mice 
NPcis mice (129/Sv) were generously provided by Karen Cichowski (Brigham and Women’s Hospital, 
Boston, Massachusetts, USA).  Mice (C57BL/6) heterozygous for disruption of the Nf1 gene were 
generously provided by Karlyne Reilly (National Cancer Institute, Frederick, Maryland, USA). Mice were 
crossed to Hsf1-modified mice (mixed 129/SvJ and Balb/cJ), a gift from Ivor Benjamin (28, University of 
Utah, Salt Lake City, Utah, USA). Moribund mice or mice with severely compromised body condition 
were euthanized, a full necropsy was performed, and all major tissues were harvested and fixed in 10% 
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formalin (soft tissues) or Bouin’s fixative (bone). Incidental tumors were documented in the spectrum of 
tumors depicted in Supplemental Fig.3B but were not included in the assessment of tumor free-survival 
(Fig. 4A). Tumors were identified and diagnosed in consultation with Roderick Bronson (Tufts 
University, Boston, Massachusetts, USA). 
 
Proliferation and survival assays 
Relative cell growth and survival was measured in 96-well microplate format using the fluorescent 
detection of resazurin dye reduction as an endpoint. Proliferation of primary MEF was measured 
following a five-day exposure to the indicated compounds. 
 
Immunoblotting and Immunoprecipitation 
Whole-cell protein extracts were prepared in cold lysis buffer (100 mM NaCl, 30 mM Tris-HCl pH 7.6, 
1% NP-40, 30 mM sodium fluoride, 1 mM EDTA, 1 mM sodium orthovanadate, and protease inhibitor 
cocktail tablet from Roche Diagnostics). Proteins were separated on SDS-PAGE gels and transferred to 
nitrocellulose membranes. Primary antibodies were applied in wash buffer for 1 hr at room temperature 
or overnight at 40C. Peroxidase-conjugated secondary antibodies were applied at room temperature for 
1 hr and signal visualized by chemiluminescent substrate (Thermo-Fisher Scientific) followed by 
exposure to film.  
 
For immunoprecipitation, 500µg of whole cell lysates were incubated with either 4µg rat monoclonal 
HSF1 antibodies (Thermo-Fisher Scientific, RT-629-PABX) or normal rat IgG overnight at 40C. Then, 
50 µl of protein G magnetic beads (GenScript) were added for 1hr at RT. After 3 times of washing with 
PBS, beads were boiled in 50µl sample loading buffer for 5 min before loading on SDS-PAGE.  
 
Immunostaining of cells and tissues 
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Archival clinical specimens and mouse tissues were processed as formalin-fixed, paraffin-embedded 
tissue blocks. Serial 4 µm sections were cut for hematoxylin and eosin staining and immunostaining.  
Detection of NFP (Monosan, clone: 2F11, 1:900), phospho-ERK (Cell Signaling Technology, #4370, 
1:500) and phospho-HSF1 (Epitomics #2092-1, 1:1200) was achieved by immunohistochemistry. 
Deparaffinized sections were blocked with 3% H2O2 and antigen retrieval was achieved using a 
pressure cooker with Dako citrate buffer (pH6.0) at 120ºC +/- 2ºC, 15 +/- 5 PSI. Primary antibodies 
were incubated on sections at room temperature for 40 min followed by 30 min incubation with Dako 
Labeled Polymer-HRP IgG as a secondary antibody. Immunoreactivity was visualized with 3,3'-
diaminobenzidine (Dako Envision+ System).  For HSF1 immunostaining, rat monoclonal antibodies 
(1:1000) were used with the ABC method. Slides were blocked with 3% normal rabbit serum. 
Biotinylated rabbit anti-rat was applied as secondary antibody (Vector Labs, BA-4000) and detection 
was achieved by 30 min incubation with Vectastain Elite ABC reagent (Vector Labs, PK-6100).  Mayer 
hematoxylin was used for counterstaining. For immunofluorescent staining, reactivity was visualized 
with secondary anti-IgG antibodies labeled with either Cy3 or Cy5. Primary antibody dilutions were anti-
HSF1 (1:250), and anti-NFP (1:300). 4',6-diamidino-2-phenylindole (DAPI, 0.5 µg/ml) was applied to 
visualize cell nuclei.  
 
Statistical methods 
All statistical analyses were performed using Prism 5.0 (GraphPad software). Statistical significance 
cut-off for all comparisons: p< 0.05. 
 
Study approval 
Paraffin blocks of human surgical resection specimens were obtained from an archive maintained by 
the Department of Pathology, Brigham and Women’s Hospital under an IRB-approved excess tissue 
protocol. Ethics committee review specifically waived the need for informed consent. All mouse 
experiments were performed under a protocol approved by the MIT Animal Care and Use Committee. 
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Figure 1. Genetic compromise of NF1 induces the heat-shock response. (A) Whole cell-based 
screen of a heat shock-oriented shRNA library.  Heat-shock reporter NIH3T3 cells arrayed in 384-well 
format were infected with lentiviral constructs designed to target 175 candidate genes. Five days later, 
reporter activation was measured by luciferase assay.  The mean Z-score calculated from 2 biological 
replicates for each construct is plotted as a measure of activation relative to the entire population of 
wells that were assayed. Two independent Nf1-targeted hairpins that strongly activate the heat-shock 
reporter are highlighted in bold. (B) Nf1 knockdown increases HSP72 expression in an immortalized 
MEF cell line. MEFs were stably transduced with two shRNAs (#39 and #42) that target different 
regions of the Nf1 mRNA and a scrambled control shRNA. Neurofibromin (NF1) and HSP72 protein 
levels were examined by immunoblotting. (C) Nf1 knockdown transcriptionally activates the heat-
shock response. Transcript levels of chaperones in Nf1-knockdown MEFs were measured by two-step 
qRT-PCR technique. Transcript levels relative to cells transduced with a scrambled control shRNA for 
each of the indicated genes were expressed as fold changes (mean±SD, n=3 or 4, Student’s t-test, * 
p<0.05; ** p<0.01; *** p<0.001). 
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Figure 2: NF1 loss activates HSF1 via 
elevated MAPK signaling. (A and B) 
Nf1 knockdown activates HSF1. 
Cytoplasmic and nuclear fractions were 
prepared from immortalized MEFs 
following overnight treatment of DMSO or 
10µM U0126. Blotting for cytoplasmic 
lactate dehydrogenase (LDH) and 
nuclear Lamins A/C confirms appropriate 
fractionation. (C and D) HSF1 is 
activated in primary Nf1-knockout MEFs. 
(E) MEK inhibition impairs HSF1 
transcriptional activity. EGFP or -HSF1 
plasmids were transfected with pHSE-
firefly luciferase reporter plasmid and 
pCMV-renilla luciferase plasmid into 
HEK293T cells. After 1 day cells were 
treated with either DMSO or 20µM 
U0126 overnight. Firefly luciferase 
signals were normalized against renilla 
luciferase signals (mean±SD, n=6, 
Student’s t-test). (F) Dominant negative 
MEK1 impairs HSF1 Ser326 
phosphorylation. EGFP or –MEK1AA 
plasmids were transfected into HEK293T 
cells and after 3 days cells were 
harvested for immunoblotting. (G) 
Dominant negative MEK1 impairs HSF1 
transcriptional activity. In HEK293T cells, 
EGFP or –MEK1AA plasmid was 
transfected with the luciferase reporter 
plasmids. Further, HSF1 plasmid was co-
transfected with either EGFP or –
MEK1AA plasmid. Three days after 
transfection, luciferase signals were 
measured (mean±SD, n=4, Student’s t-
test). (H) Proteasomal inhibition leads to 
accumulation of HSF1 protein. MEFs 
were treated with DMSO or MG132 
overnight. (I) HSF1 polyubiquitination is 
suppressed in Nf1-knockdown cells and 
re-established following MEK inhibition. 
MEFs were treated with either DMSO or 
20µM U0126 overnight and whole cell 
lysates were immunoprecipitated for 
HSF1. Normal rat IgG served as the 
control. Precipitates were immunoblotted 
for polyubiquitinated conjugates and 
HSF1. LC: light chain; WLC: whole cell 
lysates. 
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Figure 3: HSF1 activation by Nf1 knockout renders cells resistant to proteotoxic stress. Primary 
MEFs of the indicated genotypes were plated at low density (2,000 cells per well) and exposed for 5 
days to the indicated concentrations of (A) MG132, (B) Radicicol and (C) Withaferin A.  Resazurin dye 
reduction was assayed as a measure of relative viable cell number. The mean of triplicate 
determinations repeated in two separate experiments is presented. (mean±SD. ***p<.001, two-way 
ANOVA).   
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Figure 4. Genetic compromise of Hsf1 prolongs survival in a mouse model of NF1. (A) Tumor 
occurrence is suppressed in NPcis mice when Hsf1 is disrupted. Tumor-free survival in relationship to 
Hsf1 genotype is plotted for Control (NPcis +/+) and NPcis transgenic (NPcis +/-) mice. Median 
survival for NPcis mice: Hsf1 +/+ 22 weeks (n=24), Hsf1 +/- 34 weeks (n=30, Hsf1 +/+ vs +/- 
p=0.0002, Logrank test), Hsf1 -/- 29 weeks (n=19, Hsf1 +/+ vs -/- p=0.028, Log-rank test). (B) 
Representative micrographs of serial sections from MPNSTs arising in NPcis mice were 
immunostained for HSF1 to reveal increased levels in tumor but not adjacent normal nerve (NV). 
Scale bar: 100 µm..The inset shows nuclear HSF1 staining in tumors (scale bar: 10 µm). Lower 
panels were stained with hematoxylin and eosin (H&E) to demonstrate histology and provide 
orientation. (C) Survival time of NPcis mice that developed MPNST only is prolonged by Hsf1 
compromise. Median survivals: Hsf1+/+ 19 weeks, Hsf1+/- 23.5 weeks (Hsf1 +/+ vs +/- p=0.0152, 
Logrank test), Hsf1-/- 23 weeks (Hsf1 +/+ vs -/- p=0.0869, Log-rank test).  
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Figure 5. Hsf1-deficiency attenuates MAPK signaling in NPcis mice. (A) Upper: Immunoblotting 
demonstrates equivalent levels of total ERK, but less activation-associated phosphorylation (p-ERK) 
in MPNSTs arising in Hsf1 null mice. Lower: Densitometric quantitation of immunoblots confirms 
statistically significant difference in mean ratio of p-ERK to total ERK (student’s t-test). (B) Basal 
phosphorylation of ERK is diminished in NPcis-/- MEFs derived from Hsf1 heterozygous and null 
embryos. 
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Figure 6. HSF1 is 
overexpressed and activated 
in human MPNST cell lines 
lacking neurofibromin. (A) 
Immunoblotting of cell lines 
with complete loss of 
neurofibromin show elevated 
phospho-C-RAF, phospho-
MEK1/2, total and phospho-
HSF1 as well as HSP72 levels 
in comparison to lines that 
maintain full-length 
neurofibromin expression. (B) 
Immunofluorescent staining 
confirms HSF1 overexpression 
in cells without neurofibromin 
(scale bar: 25 µm). The insets 
illustrate nuclear HSF1 
staining (scale bar: 5 µm). 
DAPI counterstaining is 
presented to visualize cell 
nuclei (right panels). All 
images were acquired at 
identical magnification. (C) 
Immunoblotting of cross-linked 
cell lysates demonstrates an 
increase in activation-
associated trimeric (Tri) versus 
inactive monomeric (Mon) 
forms of HSF1 in MPNST cells 
without neurofibromin (NF1-) 
compared to lysates from 
NF1+ cell lines. The Tri/Mon 
ratio (T/M) in lysates as 
measured by densitometry is 
indicated. (D) and (E) MEK 
inhibition reduces HSF1 
Ser326 phosphorylation and 
nuclear translocation in human 
MPNST cells. S462 cells were 
treated with 20µM U0126 
overnight. Total pHSF1 
Ser326 and nuclear HSF1 
were detected by 
immunoblotting.   
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Figure 7: HSF1 knockdown impairs the growth of human MPNST cells and attenuates MAPK 
signaling. (A) Differential efficacy of HSF1-targeting shRNA constructs. S462 cells were transduced 
with control (GFP, Scram) or HSF1-targeting (hA9, hA6) lentiviral supernatants and harvested for 
immunoblotting. (B) HSF1 knockdown impairs net growth and survival of MPNST cells. After plating, 
cells were transduced with viral supernatants as indicated. Relative viable cell number in each well 
was measured 4 days after viral transduction by resazurin dye reduction assay. Raw fluorescence 
data were normalized to values obtained in wells that underwent mock transduction (mean±SD, n =5, 
***p<0.001, two-way ANOVA). (C) Decreased levels of KSR1, phospho-ERK, HSP90α and HSP72 
following HSF1 knockdown. S462 cells were stably transduced with the indicated viral supernatants 
and harvested for immunoblotting. (D) Decreased levels of KSR1 and phospho-ERK following HSP90 
inhibition. S462 cells were treated overnight with 1µM geldanamycin and harvested for 
immunoblotting. (E) KSR1 knockdown induces apoptosis in MPNST cells. S462 cells were transfected 
with either a non-targeting siRNA (NC) or 3 independent KSR1-targeting siRNAs (#1, 2, and 3) at 
25nM final concentration. Two days after transfection, cells were harvested for immunoblotting. (F) 
KSR1 knockdown impairs net growth and survival of MPNSTs. S462 cells plated in 96-well format 
were transiently transfected without or with 25nM siRNAs. Relative viable cell number in each well 
was measured as described in (B) 3 days after transfection (mean±SD, n =5, ***p<0.001, one-way 
ANOVA). 
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Figure 8: A feed-forward loop of MEK/HSF1. (A and B) Prolonged MEK inhibition decreases HSF1, 
HSP90α, and KSR1 protein levels in MPNST cells. S462 cells were treated with 20µM U0126 for 4 
days or 20µM CI-1040 for 3 days. Whole cell lysates were subjected to immunoblotting. (C) MEK 
inhibition enhances HSF1 polyubiquitination. S462 cells were treated with 20µM U0126 or CI-1040 
overnight. HSF1 polyubiquitination was detected as described in Fig. 2I. (D) MEK inhibition impairs 
net growth and survival of MPNST cells. MPNST cells were plated in 96-well format (2000 cells/well) 
and treated with DMSO or 20µM CI-1040 for 4 days. Relative viable cell number in each well was 
measured (mean±SD, n =3). (E) HSF1 overexpression increases HSP90α and KSR1 protein levels 
and enhances ERK phosphorylation. S462 cells were transduced with lentiviral LacZ or HSF1 
particles. After stable selection with blasticidin, cells were harvested for immunoblotting. (F) The 
proposed feed-forward loop of MEK/HSF1.  
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Figure 9: HSF1 is overexpressed and activated in NF1 patient tumor resections. (A) 
Photomicrographs of dual immunofluorescent staining for HSF1 (green signal) and Neurofilament 
protein (red signal). DAPI counterstaining was used to visualize cell nuclei (blue signal). Scale bar: 25 
µm. (B) Photomicrographs of immunohistochemical (IHC) staining for HSF1 and phospho-HSF1 (p-
HSF1) in a surgical specimen that captures an MPNST arising from adjacent neurofibroma. Brown 
signal depicts immunoreactivity. Pale blue counterstaining is provided by Mayer hematoxylin. Higher 
magnification images: scale bar, 25 µm; Inset images: scale bar, 10 µm; Lower magnification central 
image: scale bar, 250 µm. 
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Supplemental materials comprised of 8 figures, their legends, 2 tables, and additional 
experimental methods. 
 
Itemized list of figures and their relevance to manuscript  
Supplemental Figure 1: Supports statements in the text about the diverse functionality of HSF1-
interacting proteins and how candidate genes for shRNA knockdown were selected. 
Supplemental Figure 2: Positive control experiment for HSF1 nuclear translocation following heat 
shock and quantitation of immunoblot in Figure 2B.  
Supplemental Figure 3: In support of Figure 4, panel A presents total survival as impacted by deaths 
from both tumor-related and non-tumor related causes for control HSF1 mice (NPcis +/+, Hsf1+/+; 
NPcis +/+, Hsf1-/-). Panel B presents the effects of Hsf1 compromise on the tumor spectrum of NPcis 
mice. Panel C presents a positive correlation between glioma incidence and survival time. 
Supplemental Figure 4: Histological evidence that diverse tumor types arise in NPcis mice as claimed 
in the text. 
Supplemental Figure 5: Supports the assertion that Hsf1 compromise prolongs the tumor-free survival 
of NPcis mice. Panel A and B present insignificant effect of the genetic modifier Nstr2 on the survival 
of NPcis mice. Panel C-F present insignificant effect of sex on the survival of NPcis mice. 
Supplemental Figure 6: Supports the assertions that inhibiting HSP90 results in KSR1 destabilization 
in Figure 7 and that HSF1 overexpression increases the levels of KSR1 and ERK phosphorylation in 
Figure 8.  
Supplemental Figure 7: Immunohistochemical data supporting a key conclusion in text that HSF1 is 
preferentially over-expressed by the malignant elements within an MPNST. 
Supplemental Figure 8: Immunohistochemical evidence supporting the claim that ERK is activated to 
a much greater extent in MPNST cells than in normal nerve or benign neurofibroma. 
Supplemental Table 1: Summary of all the NPcis mice included in this study. 
Supplemental Table 2: Summary of D15mit111 and D19mit59 genotyping results. 
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Supplemental methods: 
Cells, tissues and reagents 
Human MPNST cell lines sNF96.2 (CRL-2884), sNF94.3 (CRL-2886) and sNF02.2 (CRL-2885) were 
purchased from the American Type Culture Collection (ATCC). S462 (33) and 90-8TL (34) cells were 
generously provided by Karen Cichowski (Brigham and Women’s Hospital, Boston, Massachusetts, 
USA). Primary MEF cultures were established from day E13 transgenic embryos by enzymatic 
digestion and mechanical dissociation. All cell cultures were maintained under 5% CO2 in DMEM 
(ATCC) supplemented with 10% fetal bovine serum (Sigma).  
 
          Immunoblotting and immunostaining for HSF1 were performed with a cocktail of 3 rat 
monoclonal antibodies (Ab4, Thermo-Fisher Scientific) while phosphoserine 326 HSF1 was detected 
by rabbit monoclonal antibody (Epitomics). Antibodies for total ERK, phospho-ERK, cleaved PARP, 
cleaved Caspase 7, tubulin, and lamin A/C were from Cell Signaling Technologies. KSR1 rabbit 
monoclonal antibody (EPR2421Y) was from Millipore. Neurofibromin antibody was from Santa Cruz 
Biotechnologies. HSP90 and HSP72 antibody were from Assay Designs (SPA-810) and GAPDH from 
Chemicon (MAB374). Monoclonal antibody-HRP conjugate recognizing polyubiquitinylated proteins 
was from Enzo Life Sciences (FK2H).  
 
U0126, Radicicol and MG132 were purchased from Sigma.  Withaferin A was purchased from 
Chromadex.  CI-1040 was purchased from Selleck Chem. Cytoplasmic and nuclear fractions were 
prepared using the NE-PER Nuclear protein Extraction Kit from Pierce according to manufacturer' 
instructions. 
 
Heat-shock reporter cells 
Reporter cells were generated by infecting NIH-3T3 cells with a lentiviral vector encoding a fusion 
protein consisting of enhanced GFP fused to firefly luciferase under control of HSP70B’ promoter 
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elements (14).  The plasmid encoding the fusion protein was generously provided by Khalid Shah 
(Massachusetts General Hospital, Boston, Massachusetts, USA). The recombinant reporter was 
packaged by co-transfection of 293T cells with pCMV-VSVG and pCMV-deltaVPR.  To isolate a 
homogenous population of high responding cells, a transduced culture was heat shocked at 42°C for 
1hr, then processed 8hrs later by fluorescence activated cell sorting (FACS).  Prior to use for shRNA 
screening, cells were reverse selected by FACS to eliminate a minority population of cells 
constitutively expressing the reporter in the absence of induction. 
 
High throughput production of lentiviral shRNA supernatants 
Transfection-quality DNA encoding hairpin constructs in the pLKO.1 lentiviral backbone was prepped 
using 96-well PureLink kits (Invitrogen). Average yields of 4 mg DNA/well, were quantified using a 
Pico-Green assay (Molecular Probes), and normalized robotically in each plate. Lentiviral 
supernatants were made in 96-well format by transfecting packaging cells (293T) with a three-plasmid 
system (http://www.broad.mit.edu/genome_bio/trc/rnai.html). 
 
Lentiviral infection of reporter cells  
Screening was performed in Optimem medium (Invitrogen) supplemented with 2.5% FBS. Reporter 
cells were seeded at a density of 2,000 cells/well into 384-well assay plates and allowed to adhere for 
24 hr prior to infection in the presence of polybrene (8 µg/ml) via robotic transfer of shRNA lentiviral 
supernatant (4 µl/well) from 96-well viral production plates. The following day, medium was replaced 
with fresh Optimem. All infections were performed in duplicate with an additional replicate performed 
to confirm infection efficiency by adding selection antibiotic during the medium change post infection 
(puromycin, 2 µg/ml). Five days post-infection relative viable cell number per well was monitored 
using resazurin prior to measurement of reporter induction using One-Glo luciferase assay reagent 
(Promega, 10 µl/well).  
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Primer sequences for qRT-PCR: 
	  Primers	   Sequence	  5’	  to	  3’	  
Ms_HSPA1A-­‐F	   ATGGACAAGGCGCAGATCC	  
Ms_HSPA1A-­‐R	   CTCCGACTTGTCCCCCAT	  
Ms_HSP10-­‐F	   AGTTTCTTCCGCTCTTTGACAG	  
Ms_HSP10-­‐R	   TGCCACCTTTGGTTACAGTTTC	  
Ms_Dnajb1-­‐F	   TTCGACCGCTATGGAGAGGAA	  
Ms_Dnajb1-­‐R	   CACCGAAGAACTCAGCAAACA	  
Ms_Dnajb2-­‐F	   ACCACACGCAGAATCATGGAG	  
Ms_Dnajb2-­‐R	   CTAGTGCCAGGTCATCTGGGA	  
Ms_Hspb8-­‐F	   TCCCGTGCTCCTACCCAAG	  
Ms_Hspb8-­‐R	   GCTGTCAAGTCGTCTGGAAAAG	  
Ms_HspA4L-­‐F	   TTCCTCAACTGCTACATCGCT	  
Ms_HspA4L-­‐R	   AATTGCCCAGTTAATGTCCTTGA	  
Ms_Hsp90AA1-­‐F	   AATTGCCCAGTTAATGTCCTTGA	  
Ms_Hsp90AA1-­‐F	   CGTCCGATGAATTGGAGATGAG	  
 
Primer sequences for SSLP genotyping: 
Primers Sequence	  5’	  to	  3’ 
D15mit111-F GTTTCAGAAGGCAATGTCTGG 
D15mit111-R GCTCAGTGCTAATCTCTGACTCC 
D19mit59-F CTCTAACTATCCTCTGACCTTCACA 
D19mit59-R TTTTAAGCAGAACATTGAGGACC 
 
Lentiviral shRNA knockdown 
Lentiviral shRNA plasmids targeting mouse Nf1 (NM_010897) and human Hsf1 (NM_005526) were 
obtained from the Broad Institute RNAi platform and are deposited in the Open Biosystems collection 
under the following TRCID numbers (bold font indicates text references used for each plasmid): 
Nf1:TRCN0000034339, and TRCN0000034342; HSF1:TRCN0000007480 (hA6), TRCN0000007483 
(hA9). Control hairpins targeting GFP (5’-GCAAGCTGACCCTGAAGTTCA-3’) and a scrambled 
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sequence with no known homology to any human gene (Scram; 5’-CCTAAGGTTAAGTCGCCCTCG-
3’) have been described previously (5). 
 
HSF1 trimer cross-linking: 
Equal amounts of extracted nuclear proteins were incubated with 1mM EGS (ethylene glycol 
bis[succinimidylsuccinate] (Thermo-Fisher Scientific) at RT for 30 min and the reactions were 
quenched by 50mM glycine for 15 min. The cross-linked proteins were subjected to SDS-PAGE and 
immunoblotted for HSF1. 
 
siRNA Knockdown 
KSR1-targeting siRNAs and a non-targeting siRNA were ordered from Dharmacon. siRNAs were 
transiently transfected into cells at 25nM final concentration using Lipofectamine® RNAiMAX reagent 
following the instructions (Invitrogen).  
 
Simple sequence length polymorphism (SSLP) genotyping 
Genomic DNAs were extracted from frozen tumor tissues or mouse tails. Regular PCR was applied to 
genotype Nstr1 (D19mit59 marker) and Nstr2 (D15mit111 marker) loci. PCR products were separated 
on 3% agarose gels. Genomic DNAs derived from inbred 129/SvJ or Babl/cJ mice (The Jackson 
Laboratory DNA Resource) were used to serve as positive controls.  
 
Image densitometry 
All digital western blotting images were quantitated by the free software package ImageJ according to 
the instructions.  
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Supplemental Figure 1: Immediate interacting partners of HSF1 as mined from the iHOP 
interactome database.   	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Supplemental Figure 2:  (A) Immunoblot demonstrating marked HSF1 translocation from the 
cytoplasm to nucleus following classical heat-shock (430C for 30 min) of Hsf1+/+ wild-type MEF.  
Hsf1-/- MEFs were analyzed in parallel as a specificity control for HSF1 immunoblotting. The cytosolic 
protein GAPDH and nuclear lamins A/C were blotted as controls for the fractionation procedure. (B) 
HSF1 mRNA levels in Nf1-knockdown cells. (C and D) Densitometric quantitation of immunoblot 
(Figure 2B and 2D) by ImageJ software showing reduction of HSF1 nuclear localization and pHSF1 
Ser326 following U0126 treatment.  The densities of cytoplasmic and nuclear HSF1 and pHSF1 
Ser326 were normalized against the densities of LDH and Lamin A/C respectively. The normalized 
protein levels of NF1-deficient cells (#39 and 42 or Nf1-/- cells) relative to those of the control cells 
(Scramble or Nf1+/+ cells) were expressed as fold changes. (E) Densitometric quantitation of HSF1 
levels in Figure 2H.  	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Supplemental Figure 3: (A) Kaplan-Meier analysis shows that Hsf1-/- mice have shorter overall 
survival than Hsf1+/+ mice in the absence of Nf1 alterations. (B) The incidence of most spontaneously 
arising tumor types in NPcis mice is modified by Hsf1. Compared to Hsf1 wild-type mice, the 
combined incidence of tumor histologies other than MPNST and glioma is significantly decreased in 
Hsf1 null and hemizygous knockout mice (Chi-square test). (C) The occurrence of glioma positively 
correlates with survival, which is prolonged by Hsf1-deficiency (r2=0.9283).	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Supplemental Figure 4: NPcis mice develop a broad range of malignant tumors.  Representative 
photomicrographs of H&E-stained sections demonstrate characteristic histologies for the indicated 
tumor types.  All images were acquired at the same magnification. Scale bar, 50 µm.  	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Supplemental Figure 5: (A) The previously mapped genetic modifier on chromosome 15, Nstr2, did 
not significantly affect the survival of NPcis mice. Total 33 tumors harvested from all 3 Hsf1 
experimental groups were genotyped using the simple-sequence length polymorphism (SSLP) marker 
D15mit111 to distinguish between the 129/SvJ and Balb/cJ genetic backgrounds. These mice are 
divided into groups based on D15mit111 genotypes and their survival times are compared (Student’s 
t-test, one-tailed). (B) Mice that developed MPNSTs are divided into groups based on D15mit111 
genotypes and their survival times are compared (Student’s t-test, one-tailed). (C) Sex did not 
significantly affect the survival of all NPcis mice. (D) Sex did not significantly affect the survival of 
NPcis mice that developed MPNSTs. (E) Sex also did not significantly affect the survival time of mice 
developing MPNSTs within the same Hsf1 genotypic group (Student’s t-test, two-tailed). (F) In 
contrast, Hsf1-deficient mice that developed MPNSTs had a longer survival than Hsf1 wild-type mice 
that developed MPNSTs (p=0.025, Log-rank test). 	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Supplemental Figure 6: (A) Decreased levels of KSR1, phospho-ERK1/2, and AKT following 
HSP90 inhibition.  90-8TL cells were treated overnight with 1µM geldanamycin and harvested for 
immunoblotting. (B and C) HSF1 overexpression increases the levels of HSP90α, KSR1 and 
phospho-ERK1/2 in HEK293 cells (B) and in immortalized MEFs (C). HSF1 overexpression was 
achieved by either transient transfection in HEK293 cells or stable retroviral infection in MEFs. 	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Supplemental Figure 7: HSF1 is highly overexpressed in human MPNST cells from surgical 
resection specimens. (A) H&E stain and HSF1 immunostain of a MPNST tumor section at the same 
magnification. Scale bar, 50 µm. The cells within the endoneurium of the nerve (NV) and the 
perineurium (P) show low level expression of HSF1 compared with the malignant cells. Scale bar for 
the insets, 10 µm. (B) H&E stain and HSF1 immunostain of a neurofibroma section at the same 
magnification. Scale bar, 25 µm. Many cells within benign neurofibroma (NF) show intermediate level 
expression of HSF1. Scale bar for the inset, 10 µm. 	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Supplemental Figure 8: Phospho-ERK (pERK) is markedly increased in human MPNSTs 
compared to normal nerve and benign neurofibroma. Left panels: Representative photomicrographs 
of tissue sections from two human MPNSTs stained by IHC for pERK (brown signal). Right panels: 
Sections of nerve and neurofibroma stained under identical conditions show much less pERK 
immunoreactivity. All sections were counterstained with Mayer hematoxylin (blue) and imaged at 
identical magnification. Scale bar, 25 µm. 	  
Supplemental Table 1: Summary of all NPcis mice.
ID# Hsf1 sex survival days Tumor types
195 +/+ M 174 Histiocytic sarcoma
197 +/+ F 119 ganglioneuroblastoma  
200 +/+ F 197 Autolysis
287 +/+ M 258 Angiosarcoma
288 +/+ M 256 Osteosarcoma,Histiocytic sarcoma,glioma,Angiosarcoma
289 +/+ M 183 ganglioneuroblastoma , Glioma 
292 +/+ M 98 Neuroblastoma
297 +/+ F 153 Pheochromocytoma, Rhabdomyosarcoma
300 +/+ M 91 MPNST
302 +/+ M 105 MPNST
307 +/+ F 102 MPNST
308 +/+ F 145 MPNST
311 +/+ F 193 Lymphoblastic lymphoma
330 +/+ M 126 MPNST
373 +/+ M 141 MPNST
378 +/+ M 82 MPNST
382 +/+ F 192 MPNST
388 +/+ M 192 No tumor
408 +/+ F 155 Neuroblastoma
437 +/+ M 170 MPNST
489 +/+ F 120 MPNST, lung adenoma
491 +/+ F 254 MPNST, Lymphoblastic lymphoma
619 +/+ F 162 MPNST
716 +/+ M 99 Composite tumor: Ganglioneuroblastoma/MPNST
124 +/- F 204 MPNST
126 +/- M 106 Lymphoma and Angiosarcoma
127 +/- M 265 Neurofibroma
128 +/- F 235 Histiocytic Sarcoma, Glioma
130 +/- F 350 Glioma
131 +/- F 165 MPNST
132 +/- M 252 Lymphoblastic Lymphoma
139 +/- F 185 ganglioneuroblastoma  
146 +/- F 88 No Tumor
148 +/- M 144 Composite tumor: Ganglioneuroblastoma/MPNST
150 +/- F 73 Autolysis
151 +/- F 224 Glioma, lung adenoma
152 +/- F 155 MPNST
156 +/- M 272 Autolysis
157 +/- M 122 MPNST
163 +/- M 101 No tumor
186 +/- M 265 GLIOMA
187 +/- M 243 MPNST, Glioma 
189 +/- M 252 Glioma
198 +/- F 294 MPNST, Glioma 
202 +/- F 275 Autolysis
203 +/- M 329 Autolysis
290 +/- M 112 MPNST
389 +/- M 137 MPNST
399 +/- M 266 MPNST
400 +/- M 312 MPNST
698 +/- M 260 Glioma
717 +/- M 259 MPNST
738 +/- F 198 MPNST
742 +/- F 198 ANGIOSARCOMA
134 -/- M 169 MPNST
135 -/- M 206 MPNST
159 -/- F 301 No tumor
188 -/- M 221 MPNST
196 -/- M 162 MPNST
296 -/- M 181 MPNST
316 -/- F 254 Autolysis
371 -/- F 207 Autolysis
374 -/- M 161 MPNST
404 -/- F 221 Histiocytic sarcoma, Glioma 
407 -/- F 131 MPNST
439 -/- M 57 MPNST
506 -/- M 293 No tumor
631 -/- M 203 MPNST
702 -/- F 138 MPNST
704 -/- F 208 MPNST, Glioma 
706 -/- M 132 MPNST
710 -/- F 484 No tumor
711 -/- F 232 Glioma
Supplemental Table 2: Genotypes of tumors for SSLP markers.
129/SvJ Balb/cJ 129/SvJ Balb/cJ
197 +/+ + - + - 119
289 +/+ + - + - 183
292 +/+ + + + - 98
297 +/+ + + + - 153
300 +/+ + + + - 91 Y
302 +/+ + + + - 105 Y
307 +/+ + + + - 102 Y
311 +/+ + - + - 193
330 +/+ + + + - 126 Y
373 +/+ + + + - 141 Y
382 +/+ + - + - 192 Y
408 +/+ - + + - 155
489 +/+ - + + - 120 Y
619 +/+ - + + - 162 Y
716 +/+ + + + - 99
128 +/- + - + - 235
131 +/- - + + - 165 Y
132 +/- + + + - 252
139 +/- + + + - 185
148 +/- + - + - 144
152 +/- + + + - 185 Y
157 +/- + + + - 122 Y
187 +/- + + + - 243 Y
290 +/- + - + - 112 Y
389 +/- + + + - 137 Y
134 -/- + - + - 169 Y
196 -/- + - + - 162 Y
374 -/- + + + - 161 Y
404 -/- - + + - 221
407 -/- + - + - 131 Y
631 -/- + - + - 203 Y
702 -/- + - + - 138 Y
706 -/- + - + - 132 Y
MPNST
ID#
Hsf1 genotype
D15mit111 D19mit59
Survival days
